Mitochondrial dysfunction in aging

Mitochondrial dysfunction in aging refers to the progressive loss of mitochondrial respiratory capacity, genome integrity, and quality control that accompanies age in most tissues studied. It is classed as an antagonistic hallmark in the Hallmarks of aging framework, meaning the underlying responses are protective at low intensity and damaging when chronic. The mechanism was long assumed to be self-amplifying oxidative damage; that explanation has not survived the experiments designed to test it.

§What declines

Mitochondria generate most cellular ATP through oxidative phosphorylation, buffer calcium, synthesize iron–sulfur clusters and steroid hormones, and control the intrinsic apoptosis pathway. Each carries multiple copies of a circular genome of roughly 16.5 kilobases encoding 37 genes, of which 13 are protein subunits of the respiratory chain; the remaining thousand-odd mitochondrial proteins are encoded in the nucleus and imported.

With age, measured respiratory capacity per unit of mitochondrial mass falls in muscle, liver and brain; mitochondrial morphology becomes more heterogeneous; membrane potential declines in a subset of organelles; and damaged mitochondria are cleared more slowly. In aged human skeletal muscle, individual fibres appear that lack cytochrome c oxidase activity, each traceable to a clonally expanded mitochondrial DNA deletion. Comparable clonal expansions of mtDNA deletions accumulate in substantia nigra neurons.¹ These are focal, cell-by-cell failures rather than a uniform organism-wide dimming.

§The free-radical theory and its decline

Denham Harman proposed in 1956 that aging results from cumulative damage by free radicals produced during normal metabolism, and in 1972 localized the main source to mitochondria.² The theory was attractive because it linked metabolic rate, damage, and lifespan in one causal chain, and it dominated the field for four decades. It also generated a clear prediction: reducing oxidative damage should extend lifespan.

1. 1956
   Free-radical theory proposed
   Denham Harman argues that oxygen radicals produced by metabolism damage cells cumulatively and cause aging.
2. 2004–2005
   Mutator mice
   Mice carrying a proofreading-deficient mitochondrial polymerase accumulate mtDNA mutations and show premature aging phenotypes, at mutation loads far above those seen in normal aging.
3. 2005
   One clean positive
   Targeting catalase to mitochondria extends median mouse lifespan by roughly a fifth, the strongest single result supporting the oxidative theory.
4. 2007–2011
   Antioxidant trials fail
   Meta-analyses of antioxidant supplement trials find no mortality benefit, and vitamin E is associated with increased prostate cancer risk in a large prevention trial.
5. 2009
   Genetic tests come back negative
   A review of mouse models altering antioxidant enzymes finds that most changes to oxidative defences do not alter lifespan.
6. 2013
   Mutation signature reinterpreted
   Sequencing of aged human brain shows mtDNA mutations carry a replication-error signature rather than an oxidative-damage signature.

Nearly every direct test failed. Overexpressing or deleting superoxide dismutases and glutathione peroxidases in mice generally changed oxidative damage markers without changing lifespan.³ Large randomized trials and meta-analyses of antioxidant supplements found no reduction in all-cause mortality, with signals of harm for some agents.⁴ Long-lived species do not consistently show lower radical production; naked mole-rats carry high levels of oxidative damage while living an order of magnitude longer than mice of similar size, a comparison that features in the literature on negligible senescence.

The interpretation that replaced it is mitohormesis: modest reactive oxygen species act as signals that trigger adaptive responses, and blunting them removes a stimulus the cell needs. In Caenorhabditis elegans, increasing mitochondrial superoxide can extend lifespan, and antioxidant treatment abolishes the effect. The same logic explains why antioxidant supplementation can blunt some of the adaptations produced by exercise training.

Why the reversal matters

The failure of antioxidants is the clearest case in biogerontology of a mechanistically appealing theory that did not survive intervention studies. It is the standard example cited against reasoning from plausible mechanism to expected benefit, and it is why the field now insists on lifespan and function endpoints rather than damage markers.

§mtDNA mutation and heteroplasmy

Because each cell carries many mitochondrial genomes, mutations exist as a mixture with wild-type copies, a condition called heteroplasmy. A biochemical defect usually appears only when mutant load in a cell exceeds a threshold, commonly placed between roughly 60 and 90 percent depending on the mutation and tissue. Aging tissue shows a rise not in average mutation burden across all copies, which stays low, but in the number of individual cells that have crossed the threshold through clonal expansion of a single mutant lineage.

The origin of those mutations was long assumed to be oxidative lesions. Deep sequencing of aged human brain instead found a mutational spectrum dominated by transitions consistent with errors made by the mitochondrial polymerase during replication.⁵ Mice engineered with a proofreading-deficient version of that polymerase do age prematurely, but they carry mutation loads far above anything seen in normal aging, so the model demonstrates that enough mtDNA damage causes an aging-like phenotype rather than that normal aging is caused by mtDNA damage.

§Quality control

Damaged mitochondria are removed by mitophagy, a selective branch of Autophagy. The best-characterized route depends on PINK1, which accumulates on depolarized mitochondria and recruits the ubiquitin ligase Parkin; receptor-mediated routes using BNIP3, NIX and FUNDC1 operate in parallel and dominate in some tissues. Both PINK1 and Parkin are mutated in familial early-onset Parkinson's disease, which is the strongest human evidence that failing mitochondrial quality control causes degeneration in a specific cell population.

Mitophagy is coupled to mitochondrial dynamics: fission separates damaged segments for disposal, fusion allows complementation between genomes. Markers of mitophagic flux decline with age in several model organisms, and "disabled macroautophagy" was added as a separate hallmark in 2023 in part because of this. Whether mitophagy declines with age in human tissue is harder to establish, since flux cannot be measured directly in a living person — the same measurement barrier that limits biomarker development generally.

§Interventions

Exercise remains the most reliable stimulus of mitochondrial biogenesis and the only intervention with strong human functional evidence. Among drugs and supplements, urolithin A, a gut metabolite of ellagitannins, induces mitophagy in preclinical models and has been tested in humans; randomized trials in middle-aged and in older adults have reported modest improvements in muscle endurance measures without clear gains in aerobic capacity.⁶⁷ NAD⁺ precursors are promoted partly on mitochondrial grounds, and raise blood NAD⁺ reliably while producing little demonstrated functional benefit. Elamipretide, a peptide that binds cardiolipin in the inner membrane, did not meet its primary endpoint in a phase 3 trial in primary mitochondrial myopathy, though it has continued in narrower indications.

Dietary restriction and Rapamycin both alter mitochondrial turnover, and part of their effect is attributed to enhanced quality control rather than to reduced damage. Mitochondrial-derived peptides such as humanin and MOTS-c have been proposed as signalling mediators between mitochondrial state and organismal metabolism; the human data are observational.

§Transfer, replacement, and editing

Three approaches attempt to change mitochondria rather than support them. Autologous mitochondrial transplantation — injecting mitochondria isolated from a patient's own muscle into ischaemic heart tissue — has been performed in small paediatric case series at a single centre, with encouraging but uncontrolled results. Mitochondrial replacement in the germline avoids transmitting pathogenic mtDNA by transferring nuclear material into a donor egg, and is legal in a small number of jurisdictions. Editing mtDNA directly is complicated by the fact that guide RNAs are not imported into mitochondria, which rules out standard CRISPR approaches; base editors built from a bacterial toxin that acts on double-stranded DNA have been used to install specific mtDNA edits in cells and mice, and are the leading route to a genetic intervention on the mitochondrial genome.

Whether any of this addresses aging as opposed to specific mitochondrial diseases is unresolved. The clonal expansion that produces cytochrome-oxidase-negative fibres affects a minority of cells even in old muscle, and no one has shown that correcting it restores organ-level function in an aged mammal. That gap — between a well-documented molecular lesion and a demonstrated contribution to functional decline — is the standing problem for the hallmark, and it applies with equal force to senescence and proteostasis as causal accounts.

§See also

• Hallmarks of aging
• Autophagy
• NAD+ precursors
• Mitochondrial replacement therapy
• Inflammaging
• Exercise as a geroprotector

§References